Yeast Expression Vector Construction: pPICZa-C-Flag

Immune Checkpoint Products

Immune checkpoint therapies have attracted amounts of attention from scientists who are devoted to cancer treatment. What is immune checkpoint? It is a kind of co-stimulatory and inhibitory signal for regulating the antigen recognition of T cell receptor (TCR) in the process of immune responce. When immune system is attacking pathogens, these immune checkpoints can protect the normal tissues from damage. The cancer cells cleverly escape from. immune attack by dysregulating checkpoints related proteins. Immune checkpoint therapy relys on functioning immune system with agonists of co-stimulatory signals or antagonists of inhibitory signals. Over these years there are two immune checkpoint receptors that have been actively studied: cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; also known as CD152) and programmed cell death protein 1 (PD1; also known as CD279). The corresponding antibodies can inhibit the functioning of the receptors and enhance antitumour immunity. Furthermore, multiple additional immune checkpoints, representing promising targets for anti-cancer therapy are under active development, more therapies based on immune checkpoint for more cancers are on the way to the market.

Elite blocking/ neutralizing antibodies for blockage of immune checkpoints

Molecules Product Name Antigen Species Host Ab type Catalog No.
PD-L1 / B7-H1 / CD274 PD-L1 / B7-H1 / CD274 Blocking Antibody Human Rabbit MAb 10084-R639
PD1 / PDCD1 / CD279 PD1 / PDCD1 / CD279 Neutralizing Antibody Human Mouse (humanized) MAb 10377-H944
PD1 / PDCD1 / CD279 PD1 / PDCD1 / CD279 Neutralizing Antibody Human Mouse (humanized) MAb 10377-HF06
PD1 / PDCD1 / CD279 PD1 / PDCD1 / CD279 Blocking Antibody Human Mouse (chimeric) MAb 10377-mhT28

More blocking/neutralizing antibodies

Hot targets of immune checkpoints

PD1/PDCD1/CD279 PD-L1/B7-H1/CD274 B7-DC/PD-L2/CD273 CTLA-4/CD152
CD48/SLAMF2 2B4/CD244 CD80/B7-1 CD86/B7-2
VISTA/GI24/B7-H5 TIM-3/HAVCR2 CEACAM1/CD66a CD28
B7-H3/CD276 B7-H4/B7S1/B7x SIRP alpha/CD172a CD47
OX40/CD134 ICOS Ligand/B7-H2 4-1BBL/CD137L CD137/4-1BB
CD27 CD70/CD27L/TNFSF7 CD40/TNFRSF5 CD40L/CD154/TNFSF5
CD160 BTLA HVEM/TNFRSF14 TNFSF14/LIGHT/CD258
LAG3/CD223/Lymphocyte activation gene 3 CD155/PVR OX-40L/TNFSF4/CD252 TIGIT/VSTM3
GITR/TNFRSF18 IDO1 CD226/DNAM-1 ICOS/AILIM/CD278

References

Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252–64.
Christopher J. Nirschl and Charles G. Drake. y. Molecular Pathways: Coexpression of Immune Checkpoint Molecules: Signaling Pathways and Implications for Cancer Immunotherapy. Clin Cancer Res; 19(18); 4917–24.
Lorenzo Galluzzi, Guido Kroemer & Alexander Eggermont. Novel immune checkpoint blocker approved for the treatment of advanced melanoma. OncoImmunology; 3:11; e967147.

Biology CRO Service
Biology CRO Service Introduction
Antibody Production & Development CRO Service
Protein Production CRO Service
Transient Transfection Service: Mammalian Cell Culture
Molecular Biology CRO Service
Gene Expression Vector Construction CRO Service+
- Gene Expression Vector Construction Service Description
- Mammalian Cell Expression Vector Construction Service
- Insect Cell /Baculovirus Expression Vector Construction Service
- E. Coli. Expression Vector Construction Service
- Yeast Expression Vector Construction Service
Yeast Expression Vector Construction Service Description
Yeast Expression Vector Construction: pPICZa-N-Flag
Yeast Expression Vector Construction: pPICZa-N-His
Yeast Expression Vector Construction: pPICZa-N-HA
Yeast Expression Vector Construction: pPICZa-N-Myc
Yeast Expression Vector Construction: untagged
Yeast Expression Vector Construction: pPICZa-C-Flag
Yeast Expression Vector Construction: pPICZa-C-His
Yeast Expression Vector Construction: pPICZa-C-HA
Yeast Expression Vector Construction: pPICZa-C-Myc